Erin Weeda to Anticoagulants
This is a "connection" page, showing publications Erin Weeda has written about Anticoagulants.
Connection Strength
1.684
-
Systematic Review of Real-World Studies Evaluating Characteristics Associated With or Programs Designed to Facilitate Outpatient Management of Deep Vein Thrombosis. Clin Appl Thromb Hemost. 2018 Dec; 24(9_suppl):301S-313S.
Score: 0.504
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.443
-
Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. Curr Med Res Opin. 2016 06; 32(6):1117-20.
Score: 0.419
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.109
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.109
-
Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. Ann Pharmacother. 2022 05; 56(5):541-547.
Score: 0.038
-
Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018 10 01; 4(4):328-329.
Score: 0.031
-
Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. Clin Cardiol. 2018 Jan; 41(1):119-125.
Score: 0.030